DK1587832T3 - Factor VIII polypeptide - Google Patents

Factor VIII polypeptide Download PDF

Info

Publication number
DK1587832T3
DK1587832T3 DK03759019.7T DK03759019T DK1587832T3 DK 1587832 T3 DK1587832 T3 DK 1587832T3 DK 03759019 T DK03759019 T DK 03759019T DK 1587832 T3 DK1587832 T3 DK 1587832T3
Authority
DK
Denmark
Prior art keywords
fviii
ser
leu
thr
polypeptide
Prior art date
Application number
DK03759019.7T
Other languages
Danish (da)
English (en)
Inventor
Hun-Taek Kim
In-Young Song
Jin-Wook Jang
Yong-Kook Kim
Ho Soon Lee
Yung-Jue Bang
Dae-Kee Kim
Jae Won Choi
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Application granted granted Critical
Publication of DK1587832T3 publication Critical patent/DK1587832T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/10Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03759019.7T 2003-01-28 2003-10-27 Factor VIII polypeptide DK1587832T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide
PCT/KR2003/002277 WO2004067566A1 (en) 2003-01-28 2003-10-27 Factor viii polypeptide

Publications (1)

Publication Number Publication Date
DK1587832T3 true DK1587832T3 (en) 2014-02-24

Family

ID=32736253

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03759019.7T DK1587832T3 (en) 2003-01-28 2003-10-27 Factor VIII polypeptide
DK10171071.3T DK2253645T3 (en) 2003-01-28 2003-10-27 Factor VIII-polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10171071.3T DK2253645T3 (en) 2003-01-28 2003-10-27 Factor VIII-polypeptide

Country Status (13)

Country Link
US (1) US7041635B2 (enExample)
EP (2) EP2253645B1 (enExample)
KR (1) KR100642293B1 (enExample)
CN (1) CN100404552C (enExample)
AU (1) AU2003274766B8 (enExample)
BE (1) BE2017C021I2 (enExample)
CA (1) CA2514646C (enExample)
DK (2) DK1587832T3 (enExample)
ES (1) ES2446041T3 (enExample)
FR (1) FR17C1024I2 (enExample)
LU (1) LUC00023I2 (enExample)
NL (1) NL300878I2 (enExample)
WO (1) WO2004067566A1 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20110124565A1 (en) * 2005-04-14 2011-05-26 Hans-Peter Hauser Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
PT2126106T (pt) 2007-02-23 2017-12-12 Sk Chemicals Co Ltd Proceso para produzir e purificar o fator viii e seus derivados
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
EP2209908B1 (en) * 2007-11-01 2014-09-03 University Of Rochester Recombinant factor viii having increased stability
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
CA2724630A1 (en) * 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
DK2482841T4 (da) 2009-10-02 2022-10-24 Childrens Hospital Philadelphia Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
CA2816575C (en) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
AU2012318292B2 (en) * 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
KR20140083035A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 viii의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
CN111499761A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
AU2013290173B2 (en) 2012-07-11 2018-02-15 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP3666283B1 (en) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PH12016501323B1 (en) 2014-01-10 2022-04-29 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
CA2934705C (en) * 2014-01-20 2020-03-31 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
NZ729629A (en) 2014-08-04 2021-12-24 Csl Ltd Factor viii formulation
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3374388A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
EP3476860A4 (en) 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第viii因子とその誘導体の製造及び精製方法
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥方法
SG11202007114VA (en) 2018-02-01 2020-08-28 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii
MX2020010369A (es) 2018-04-04 2020-10-22 Sigilon Therapeutics Inc Particulas implantables y metodos relacionados.
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病aを処置する方法
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP2022501373A (ja) * 2018-09-19 2022-01-06 セル マシン,インコーポレイテッド 改善された第viii因子長期半減期凝固複合体に関連する方法および組成物
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020168362A1 (en) * 2019-02-15 2020-08-20 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
JP7541993B2 (ja) 2019-03-14 2024-08-29 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥用ローディングトレイ組立体、凍結乾燥システム及び凍結乾燥方法
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
JP7585217B2 (ja) * 2019-06-05 2024-11-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 改善された第viii因子発現による血友病aのための遺伝子編集
JP2022537200A (ja) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド 血友病および低骨ミネラル密度を処置するための方法および組成物
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP7681268B2 (ja) * 2020-03-30 2025-05-22 シスメックス株式会社 血液凝固活性の測定方法
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2024527252A (ja) 2021-06-14 2024-07-24 武田薬品工業株式会社 発現の増加した組み換えfviiiバリアントをコードするウイルスベクターを用いた、血友病aの遺伝子療法
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE69333928T2 (de) * 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
EP0910628B1 (en) * 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
NZ530131A (en) 2001-06-15 2005-12-23 Andre C Gene therapy for hemophilia A

Also Published As

Publication number Publication date
EP2253645A3 (en) 2011-02-16
CA2514646A1 (en) 2004-08-12
WO2004067566A1 (en) 2004-08-12
EP1587832A1 (en) 2005-10-26
KR100642293B1 (ko) 2006-11-03
CA2514646C (en) 2013-07-23
ES2446041T3 (es) 2014-03-06
US7041635B2 (en) 2006-05-09
NL300878I2 (nl) 2017-11-02
AU2003274766B2 (en) 2009-02-12
KR20050044776A (ko) 2005-05-12
FR17C1024I1 (enExample) 2017-09-08
DK2253645T3 (en) 2016-06-27
EP2253645B1 (en) 2016-03-23
LUC00023I1 (enExample) 2017-06-21
LUC00023I2 (enExample) 2017-09-08
EP2253645A2 (en) 2010-11-24
AU2003274766A1 (en) 2004-08-23
EP1587832B1 (en) 2013-12-11
CN100404552C (zh) 2008-07-23
AU2003274766B8 (en) 2009-08-27
CN1745100A (zh) 2006-03-08
FR17C1024I2 (fr) 2019-07-19
HK1150840A1 (en) 2012-01-13
US20040147436A1 (en) 2004-07-29
BE2017C021I2 (enExample) 2023-03-07

Similar Documents

Publication Publication Date Title
DK1587832T3 (en) Factor VIII polypeptide
EP0939767B1 (en) Porcine factor viii and hybrids thereof
EP1200105B1 (en) Modified factor viii
US6458563B1 (en) Modified factor VIII
US20050123997A1 (en) Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
AU2001238416A1 (en) Modified factor VIII
US20150352190A1 (en) Modified Factor VIII
EP1062224A4 (en) MODIFIED FACTOR VIII
WO2003087355A1 (en) Inactivation resistant factor viii
AU2002364509A1 (en) Factor viii c2 domain variants
HK1150840B (en) Factor viii polypeptide
HK1022480B (en) Porcine factor viii and hybrids thereof
HK1078596A (en) Modified factor viii